Background. Chronic kidney disease (CKD) seems to be common in long-term survivors of haematopoietic cell transplantation (HCT). However, the range of its frequency is very wide, likely due to variability in the definitions of CKD and the periods of follow-up. Methods. We conducted a cross-sectional and retrospective study in 158 adults who received myeloablative allogeneic HCT for lymphohaematologic malignancies at least 3 years ago and are alive today. The mean survival time was 6.15 ± 4.88 years (range: 3-16 years). CKD was defined as a sustained decrease in glomerular filtration rate (GFR) or persistent proteinuria for a period more than 3 months. GFR was calculated based on serum creatinine (Cr) using the Modification of Diet in Renal Disease formula. Serum Cr and proteinuria were measured at least on three occasions separated by one or more months before the investigation. CKD was classified according to the National Kidney Foundation CKD staging. Proteinuria was defined as positive dipstick test ≥1+. The factors associated with the presence of CKD with a decrease of GFR (CKD ≥ stage 3) were examined using multivariate logistic regression analysis, adjusted for demographic and clinical characteristics. Results. The prevalence of proteinuria was found in 36 out of 158 patients (22.8%). The prevalence of each CKD stage was as follows: Stage 0 (no CKD), 98 patients (62.0%); Stage 1, 18 patients (11.4%); Stage 2, 15 patients (9.5%); Stage 3, 8 patients (5.1%); Stage 4, 10 patients (6.3%) and Stage 5, 9 patients (5.7%). Initiation of chronic dialysis treatment or transplant was performed in seven CKD stage-5 patients (4.4%) at a mean of 10.9 ± 3.72 years after HCT. Multivariate analysis identified acute kidney injury with HCT [odds ratio (OR), 9.920; 95% confidence interval (CI), 2.084-39.68; P = 0.0051], hypertension after HCT (OR, 4.031; 95% CI, 1.044-13.06; P = 0.0346) and survival time after HCT (OR, 4.275; 95% CI,; P = 0.0481) as significant factors associated with the presence of CKD ≥ stage 3.
Introduction
Haematopoietic cell transplantation (HCT) is a notable treatment that provides a radical cure for haematological malignancies and, as such, has contributed greatly to improvements in the quality of life and survival of patients with these disorders. Transplanted patients experience various kidney diseases throughout the clinical course following HCT. Acute kidney injury (AKI) develops in the acute phase of HCT and represents the most critical complication, as it largely governs the fate of the patients [1, 2] . Some patients who overcome AKI and survive develop the nephrotic syndrome within several years after HCT as a result of chronic graft-versus-host disease (GVHD) [3, 4] . Chronic kidney disease (CKD) finally develops in those patients who survive these previous events [5, 6] .
In general, CKD is increasingly recognized as a global public health problem. Outcomes of CKD include not only progression to end-stage renal disease (ESRD) but also complications of reduced kidney function and increased risk of other chronic diseases such as cardiovascular disease (CVD), infections and cancer [7] . Patients with CKD are more likely to die than to develop kidney failure. Thus, HCT survivors who develop CKD may carry a great risk for death, CVD events and hospitalization [8] . In fact, a study CKD in long-term survivors of HCT 279 on 100 000 survivors of HCT who received their graft at least 5 years ago showed that the overall burden of CKD in HCT represented a significant public health problem in the United States [9] . Prevention and good treatment of CKD in long-term survivors of HCT is therefore an important issue that needs to be addressed by nephrologists, cardiologists and transplant physicians.
The lack of a consistent definition of post-HCT CKD has made it difficult to draw comparisons across previous studies and to identify risk factors of post-HCT CKD. Detection, evaluation and management of CKD according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline [10] has been accepted and has facilitated comparisons between studies on CKD. Therefore, we attempted to determine the prevalence of CKD in long-term survivors of HCT (≥3 years) and to characterize risk factors for progression to renal failure by using the K/DOQI classification.
Methods

Subjects
The subjects in the study included 158 adult patients (98 males, 60 females; mean patient age, 32.0 ± 9.48 years) who received myeloablative allogeneic HCT at the Department of Hematology in Tokyo Metropolitan Cancer Center, Komagome Hospital, between January 1987 and December 2003. All patients had received HCT at least 3 years ago, had long-term follow-up of serum creatinine (Cr) and proteinuria data (range: 3-16 years) and were alive at the time of investigation (December 2007). Serum Cr and proteinuria had been measured at least on three occasions separated by one or more months before the investigation. Prior to HCT, all patients had normal urinalysis with creatinine (Cr) clearance measured in a 24-h timed urine sample being ≥80 mL/min. No patients had morphological abnormalities of the kidney, hypertension, cardiac dysfunction or diabetic mellitus. The underlying lymphohaematological diseases were chronic myelocytic leukaemia (n = 63), acute myelocytic leukaemia (n = 32), acute lymphocytic leucaemia (n = 26), refractory anaemia (n = 18), myelodysplastic syndrome (n = 12), non-Hodgkin's lymphoma (n = 4), myelofibrosis (n = 2) and multiple myeloma (n = 1). Transplant modality was related bone marrow transplantation (BMT) (n = 75), unrelated BMT (n = 28), umbilical cord blood stem cell transplantation (CBT) (n = 18) and peripheral blood stem cell transplantation (PBT) (n = 37). The study was conducted in accordance with the declaration of Helsinki and was approved by the institutional review board.
Definition of post-HCT CKD
Post-HCT CKD was defined as a sustained abnormality in glomerular filtration rate (GFR) as described below or persistent proteinuria for a period of more than 3 months. We used the Modification of 
Myeloablative procedure
The most common conditioning regimen used in the myeloablative patients was cytarabine (2 g/m 2 × 2 times/day × 3 days) plus cyclophosphamide (60 mg/kg × 2 days) combined with fractionated total body irradiation (TBI; 4 Gy/day × 3 days). Selective kidney shielding blocks were used during TBI and these reduced the renal dose to 10 Gy [12] . Post-transplantation immunosuppression consisted of a short course of methotrexate (MTX) and cyclosporine (CSP). MTX was administered at 15 mg/m 2 IV on day +1 and at 10 mg/m 2 /day on days +3, +6 and +11. CSP was started at 1.5 mg/kg IV twice a day, and then switched to oral administration, with the dose being gradually decreased from day +50 until day +180. Prophylaxis for infections included acyclovir for herpes simplex virus, trimethoprim/sulfamethoxazole to prevent Pneumocystis jiroveci and Pneumocystis carinii infection, oral fluconazole for candida infection and pre-emptive ganciclovir for cytomegalovirus disease among viraemic patients.
Variables and analytic methods
Data are expressed as mean ± standard deviation (SD) unless otherwise stated. The clinical characteristics between high-and low-stage CKD patients were compared for statistical significance using the Mann-Whitney U test for continuous variables and the chi-square test for categorical variables of percentages. The factors associated with the presence of CKD with a decrease in GFR (CKD ≥ stage 3) were examined using multivariate logistic regression analysis, adjusted for demographic and clinical characteristics. The associations evaluated included age, gender, long-term use of calcineurin inhibitor (>180 days), presence of chronic graft-versushost disease (GVHD), experience of acute GVHD (≥ grade II), total body irradiation (TBI), presence of proteinuria, AKI in the post-HCT periods and newly developed hypertension after HCT. AKI following HCT was defined as a ≥2-fold increase in serum Cr values to severe acute renal failure requiring dialysis therapy within 100 days after HCT [1, 2] . Hypertension was defined as a continual rise in systolic blood pressure to ≥140 mmHg after HCT. Diabetes mellitus was defined as use of insulin or oral hypoglycaemic agents, or a fasting glucose of >125 mg/dL. JMP software version 7 (SAS Institute, Tokyo, Japan) was used for the statistical analyses. P-values < 0.05 were considered to indicate significant differences. 
Results
Prevalence of proteinuria and each CKD stage
Clinical characteristics in CKD with a decrease in GFR
(CKD ≥ stage 3) Table 2 depicts the clinical characteristics of the patients with CKD ≥ stage 3 (n = 27) in comparison with those with CKD stages 0-2 (n = 131). The mean age was significantly higher in patients with CKD ≥ stage 3 (P = 0.0001). The mean follow-up period (survival time) after HCT in patients with CKD ≥ stage 3 was significantly longer than in those with CKD stages 0-2 (P = 0.0020). The proportions of AKI and hypertension occurred during the peri-and post-HCT periods were significantly higher in patients with CKD ≥ stage 3 (P ≤ 0.0001 and P = 0.0032, respectively). Hypertension developed at a median of 268 days post-HCT with a range of 101-459 days in CKD ≥ stage 3. CKD ≥ stage 3 developed at a median of 306 days post-HCT with a range of 118-612 days. The proportions of TBI recipients and diabetes mellitus post-HCT were not statistically different between the two CKD groups. Table 3 lists the factors that showed significant associations with the presence of CKD ≥ stage 3 in the multivariate logistic regression analysis. AKI and hypertension during post-HCT periods and survival time after HCT were identified as significant factors associated with such CKD. Age at HCT, gender, presence of proteinuria, coexisting of diabetes, experience of TBI, experience of chronic and acute GVHD and long-term use of calcineurin inhibitors were not related significantly to the presence of CKD ≥ stage 3. 
Factors associated with the presence of CKD ≥ stage 3
Progression of CKD to ESRD
Seven CKD patients (4.4%) eventually developed ESRD. One female ESRD patient received a kidney transplant from the same donor as her stem cells. Table 4 shows a summary of these seven ESRD patients, three (49%) of whom received TBI, whereas the remaining four patients did not. The mean age of the patients at HCT and at the onset of CKD was 33.1 ± 9.36 years and 34.9 ± 8.69 years, respectively. The mean age at initiation of dialysis or transplant was 44.0 ± 10.1 years, while the mean duration from HCT to ESRD was 10.9 ± 3.72 years.
Discussion
This is the first detailed study to report the prevalence of each CKD stage based on the K/DOQI classification in long-term survivors of myeloablative allogeneic HCT. A remarkable high percentage of post-HCT patients had evidence of proteinuria and all stages of CKD. The risk factors associated with CKD ≥ stage 3 were persistent AKI, post-HCT hypertension and patients' longevity, whereas proteinuria, TBI, acute and chronic GVHD and long-term use of calcineurin inhibitors were not contributing factors. The present study showed that the prevalence of all stages of CKD was 44.3%, while that of CKD ≥ stage 3 was 17.1%. Hingorani et al. performed the largest cohort study of 1635 HCT patients and showed that the incidence rate of CKD with GFR< 60 mL/min/1.73 m 2 , corresponding to CKD ≥ stage 3, was 23% in survivors (>+day 100 after transplant) [13] . This incidence was higher than ours; however, the cohort included patients receiving different types of transplant, paediatric patients and patients with no malignant underlying diseases. In addition, the follow-up periods after HCT were relatively short (+131-516 days). Choi et al. studied the prevalence of post-HCT CKD based on the K/DOQI criteria in 1190 adult long-term survivors whose median follow-up period was 7.1 years (range: 1-24.3 years) [14] . The prevalence of CKD ≥ stage 3 was 4.5% (matched-sibling HCT) to 10% (unrelated donor HCT) at 5 years after HCT in allogeneic HCT. These frequencies were much lower than ours in spite of the data including patients receiving nonmyeloablative allogeneic HCT among whom the high rate of CKD was reported [15] . The study was almost identical to ours in the methods, but they did not show the prevalence of CKD less than stage 3 in the population. Further accumulation of epidemiological data of post-HCT CKD, adjusted for the K/DOQI staging, study populations and follow-up periods will be warranted.
Our study focused on the risk of progressing to ESRD in post-HCT CKD patients [16, 17] . Seven patients with stage-5 CKD developed ESRD within ∼11 years after HCT. The progression from CKD to ESRD in these patients occurred within 4 years from March 2003 to December 2007. That is, 7 of the 158 HCT survivors developed ESRD within this 4-year period, which equated to an incidence of ESRD at our hospital of ∼110 persons/10 000 HCT survivor-years. The incidence of ESRD has been reported to be 0.07-0.12/10 000 in the general Japanese population matched for age (44 years) with the HCT-ESRD patients [18] . This indicates that long-term survivors of HCT develop ESRD at a considerably higher rate than at the general rate. Similar rates have been reported in long-term survivors of HCT in the United States [19] . An increase in the prevalence of CKD and ESRD in long-term survivors of HCT is therefore expected, despite the lifespan of HCT-ESRD patients being shorter than that of typical ESRD patients [20] . CKD is generally thought to be a great risk for chronic diseases such as CVD, infections and cancer as well as ESRD [7] . The overall burden of CKD in the surviving patients has significant medical and economic implications, given the trend towards increasing longevity in the recipients of HCT. It is likely that persistent AKI is relevant to the development of CKD ≥ stage 3. The incidence of AKI after HCT, defined as a doubling of baseline serum Cr within the first 100 days after HCT, varies from 21 to 80% in the literature [2] . Previous studies have shown that post-HCT AKI is a risk factor for CKD in both adult and paediatric cohorts [5, [13] [14] [15] . This may also suggest that the prevention of AKI in the early HCT period has the potential to prevent advanced CKD leading to ESRD. Newly developed hypertension following HCT was another significant factor associated with CKD. It is possible, however, that hypertension may be an effect of CKD, rather than a primary cause of CKD. Persistent hypertension due to CKD following HCT may therefore be involved in the progression of CKD over the long term. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are promising agents for treating this condition, as they have been shown to delay progress of radiation nephropathy in an animal model [21] . In addition, a recent report demonstrated that angiotensin-converting enzyme inhibitors are useful for slowing the reduction in renal function in post-HCT CKD patients [22] .
The impact of TBI on CKD following HCT seems to be controversial. A series of clinical and animal studies by Cohen et al. emphasized that initial endothelial damage of intrarenal vessels caused by TBI was the most important factor responsible for the subsequent development of post-HCT renal dysfunction [23] and demonstrated a direct dose-response relationship between TBI dose and the frequency of post-HCT renal dysfunction [24] . In contrast, the recent large cohort studies have not found that TBI is statistically associated with CKD when it was defined based on estimated GFR [13, 14] . As for our results, the statistical analysis did not show that TBI was a significant contributor to advanced CKD, either. As a matter of fact, the use of selective renal shielding blocks during TBI was started in our hospital in March 1999 with the aim of reducing the frequency of kidney disease following HCT. Following the introduction of the blocks, the renal dysfunction-free rates in our hospital increased from 78.5% to 100% 2 years after HCT in 109 patients with leucaemia who received TBI [12] . In addition, a cell biological study has recently suggested that kidney shielding may preserve kidney stem cells that reside in the papilla, thereby enabling kidney repair and recovery [1, 25] . Therefore, a possible reason for our success in avoiding the adverse impact of TBI on advanced CKD might in part include the use of selective renal shielding blocks during TBI.
There were some limitations in this study due to its retrospective observational design. Therefore, these results can only demonstrate associations rather than specific causes. No renal biopsy has been performed because of the perceived risks of the procedure in this patient population although it is very important to learn causes associated with CKD on a pathological basis. In addition, we were not able to compare the current and previous prevalence of CKD, as no adequate data were available before March 1999. A prospective study is, therefore, required to confirm the significance of the use of kidney shielding blocks in the TBI procedure, AKI during the peri-and post-HCT periods and comprehensive treatment of hypertension.
In conclusion, the number of HCTs performed keeps increasing with an associated rise in success rate worldwide. More than 10 000 HCT are conducted annually in the world (∼1000 in Japan). An increase of CKD survivors who are at a high risk for other chronic diseases is therefore expected. The recognition of post-HCT CKD should be evolved across the world. Physicians including nephrologists, cardiologists and oncologists, and public health officials will need to work together in order to identify transplanted patients at a risk of developing CKD, thereby slowing the progression to ESRD or preventing chronic complications.
